Wall Street analysts are by and large predicting good things for Abbott (NYSE:ABT) after it spins out its branded pharmaceuticals division, to be named AbbVie, early next year.
But, although some are decidedly bullish on ABT, others are taking a more cautious approach until more is known about the structure of the deal.